• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Eyecare Leadership

anonymous

Guest
Just curious as a previous employee and someone who is still heavily invested in the company stock (I know, i know, I should have sold long ago!) What did they do with the leadership trip for the year 2017? After laying off so many, I can’t see how they could still go ahead with it. And what about the employees who would have won but were let go?